November 25, 2016
CSL Behring Japan Pres. Jean-Marc Morange CSL Behring will launch its hemophilia B treatment Idelvion (albutrepenonacog alfa) in Japan on November 29, marking its entry into the Japanese hemophilia market. At a Tokyo press seminar held on November 22, the...read more